معرفی
Daniel LÉVESQUE is a Professor at the University of Montreal's Faculty of Pharmacy, where he also serves as Director and Associate Vice-Rector for Graduate and Postdoctoral Studies. His leadership extends to membership in three key research groups: Neural Signalling and Circuitry (SNC), University Research Group on Medicines (GRUM), and the Interdisciplinary Research Centre on the Brain and Learning (CIRCA).
He holds a PhD in Pharmacy from Université Laval (1991) and completed postdoctoral training in Neuroscience at INSERM U109 in France (1995).
LÉVESQUE's research focuses on therapeutic target discovery for central nervous system disorders, with expertise in Parkinson's disease, neurodegenerative diseases, and pharmacotherapy. His work investigates molecular mechanisms of antipsychotic drugs, dopamine dysregulation, and nuclear receptors (Nur77/RXR). Key areas include tardive dyskinesia pathology, L-Dopa-induced dyskinesia management, and neural adaptations in addiction.
His 15 most recent publications (2017–2022) predominantly explore Parkinson's disease mechanisms, tardive dyskinesia, antipsychotic drug effects, and Nur77 receptor biology. These studies employ diverse methodologies from molecular biology to primate neuropathology, emphasizing translational neuropharmacology.
He has supervised 8 graduate students (5 PhD, 3 Master's) between 2012–2023, with projects spanning Nur77 modulation, tardive dyskinesia characterization, and antipsychotic mechanisms. Major grants include funding from IRSC, FRQS, and Medicament Québec for projects such as:
- Nur77/RXR modulation for Parkinson's dyskinesia (IRICoR, 2020–2023)
- Mechanisms of antipsychotic-induced dopamine supersensitivity (IRSC, 2013–2021)
- Infrastructure support for neural circuitry research (FRQS, 2002–2020)
LÉVESQUE leads collaborative projects with researchers like Sylvie Mader and Claude Rouillard, working within dedicated teams at SNC, GRUM, and CIRCA to advance neuropharmacology and therapeutic development.
